Roche Holding AG’s lung cancer drug scored a big win against a standard therapy in a study this week. Now, the Swiss drugmaker is turning to artificial intelligence to find patients who can benefit. When given after surgery to remove lung tumors, Roche’s Alecensa cut the risk of either cancer recurrence or death by 76% […]
